<DOC>
	<DOC>NCT00246922</DOC>
	<brief_summary>The aim of this long-term study is to investigate the effect of roflumilast (APTA-2217) on the long-term safety in patients with asthma, who completed the 24-week evaluation of study APTA-2217-05. Roflumilast will be administered orally once daily. The present study consists of a 28 weeks treatment period, and is the extension of the 24-week study APTA-2217-05 (registered study). The study will provide further long-term safety and efficacy data of roflumilast.</brief_summary>
	<brief_title>Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Main inclusion criteria: Patients with asthma disease Written informed consent Patients who completed the 24week evaluation of study APTA221705 Main exclusion criteria: % FEV1.0 &lt; 60% at both 18 weeks and 24 weeks measurements during APTA221705 Patients with poorly controlled asthma between informed consent day and study starting day: need for oral or intravenous steroid therapy, hospitalization or any emergency visit, PEF value worsened for 2 or more consecutive days Serious diseases</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Roflumilast</keyword>
	<keyword>phosphodiesterase 4 inhibitor</keyword>
</DOC>